Mario Sznol

Author PubWeight™ 161.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 17.53
3 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
4 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
5 Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012 7.00
6 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012 5.32
7 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010 4.50
8 Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002 4.15
9 A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007 2.97
10 Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011 2.90
11 Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010 2.65
12 Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012 2.28
13 Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009 2.13
14 Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park) 2013 2.05
15 Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010 2.00
16 MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 2011 1.99
17 Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009 1.80
18 Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 2007 1.57
19 Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003 1.40
20 A phase 2 trial of dasatinib in advanced melanoma. Cancer 2010 1.40
21 Melanoma: a model for testing new agents in combination therapies. J Transl Med 2010 1.39
22 Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014 1.30
23 White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011 1.27
24 Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003 1.24
25 Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med 2011 1.23
26 Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005 1.22
27 The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007 1.21
28 Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004 1.16
29 A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 2004 1.14
30 Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005 1.13
31 Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003 1.13
32 Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008 1.13
33 Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 2011 1.12
34 A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 2004 1.08
35 A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer. PLoS One 2013 1.08
36 Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 2008 1.07
37 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
38 Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006 1.01
39 Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006 1.00
40 Ipilimumab-induced perforating colitis. J Clin Gastroenterol 2013 1.00
41 Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2014 0.99
42 A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res 2007 0.97
43 C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res 2009 0.97
44 Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 2005 0.90
45 Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer 2011 0.90
46 Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 2005 0.90
47 A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 2005 0.90
48 Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? Curr Opin Investig Drugs 2010 0.87
49 In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res 2011 0.83
50 Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. J Clin Oncol 2011 0.81
51 Chitinase-like proteins in lung injury, repair, and metastasis. Proc Am Thorac Soc 2012 0.81
52 Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation. Cornea 2016 0.75
53 Relative roles of targeted therapies and immunotherapies in melanoma. Oncology (Williston Park) 2012 0.75
54 Developing enabling technologies for the success of cancer immunotherapy. Curr Opin Investig Drugs 2004 0.75